22 February 2002
An open-label study to evaluate the safety, tolerability and efficacy of rivastigmine in patients with mild to moderate probable Alzheimer's disease in the community setting.
Maria Barcikowska, Anna Pfeffer, Stanisław Ochudło, Krzysztof Sołtys, Joanna Łapin, Stanisław Puzyński, Ryszard Podemski, Grzegorz Opala, Adam Bilikiewicz, Małgorzata Bilińska, Bogusław Paradowski, Tadeusz Parnowski, Tomasz GabryelewiczMed Sci Monit 2002; 8(2): PI9-15 :: ID: 420923
Abstract
BACKGROUND: Long-term safety and efficacy of Exelon (rivastigmine) wasevaluated in a multi-center open-label study of 62 patients with probable mild to moderate Alzheimer'sdisease living in community setting. MATERIAL/METHODS: The patients started treatment with 1.5 mg bid(3 mg/day) Exelon and were scheduled to receive doses of 1.5 mg bid Exelon escalating on a biweekly basis.The patients were maintained on the highest tolerated dose within the assigned dose range 1.5-6.0 mgbid (3-12 mg/day) for the rest of the study. Evaluations were scheduled at biweekly intervals for thefirst 8 weeks and subsequently at study weeks 12, 18 and 26. Effects of Exelon on cognition were evaluatedusing the mini-mental state examination (MMSE) and selected items of Alzheimer's disease assessment scale(ADAS-cog) and the staging of the disease was measured using the global deterioration scale (GDS). Safetywas monitored by physical examinations, vital signs, laboratory tests, ECG recording and by the assessmentof adverse events. RESULTS: 55 patients completed the study (89%). Patients treated for 26 weeks showedthe mean MMSE, ADAS-cog and GDS scores close to baseline values (p=NS) with no improvement and no deterioration.Exelon was generally well tolerated with 11% of patients withdrawing due to adverse events. The mostfrequently reported adverse events related to the gastrointestinal tract. CONCLUSIONS: In conclusion,the study data indicate that treatment with Exelon is safe, generally well tolerated and inhibits theprogression of cognitive decline in patients with mild to moderate Alzheimer's disease over 26 weeksof treatment.
Keywords: Aged, 80 and over, Alzheimer Disease, Carbamates, Disease Progression, Neuroprotective Agents, Phenylcarbamates, Research Support, Non-U.S. Gov
Editorial
04 June 2022 : Editorial
Editorial: Acute Hepatitis of Unknown Origin in Children. Is Autoimmunity at Play?DOI: 10.12659/MSM.937371
Med Sci Monit 2022; 28:e937371
In Press
23 Jun 2022 : Clinical Research
A Real-World Study to Compare the Safety and Efficacy of Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir, w...Med Sci Monit In Press; DOI: 10.12659/MSM.936706
22 Jun 2022 : Clinical Research
A Single-Center Study Comparing the Effects of Thoracic Spine Manipulation vs Mobility Exercises in 26 Offi...Med Sci Monit In Press; DOI: 10.12659/MSM.937316
21 Jun 2022 : Clinical Research
Optimal Timing and Outcomes of Minimally Invasive Approach in Acute Biliary PancreatitisMed Sci Monit In Press; DOI: 10.12659/MSM.937016
16 Jun 2022 : Clinical Research
Renal Manifestations in Inflammatory Bowel Disease: A Cohort Study During the Biologic EraMed Sci Monit In Press; DOI: 10.12659/MSM.936497
Most Viewed Current Articles
30 Dec 2021 : Clinical Research
Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...DOI :10.12659/MSM.935379
Med Sci Monit 2021; 27:e935379
08 Mar 2022 : Review article
A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...DOI :10.12659/MSM.936292
Med Sci Monit 2022; 28:e936292
01 Nov 2020 : Review article
Long-Term Respiratory and Neurological Sequelae of COVID-19DOI :10.12659/MSM.928996
Med Sci Monit 2020; 26:e928996
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952